Fangfang Duan, Shanshan Song, Hang Zhai, Yazhi Wang, Jun Cheng, Song Yang
{"title":"Propensity Score Matching Analysis for Alcohol-Related Liver Disease.","authors":"Fangfang Duan, Shanshan Song, Hang Zhai, Yazhi Wang, Jun Cheng, Song Yang","doi":"10.1002/hsr2.70257","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to investigate the impact of comorbidity with chronic hepatitis B (CHB) on the survival rates and incidence of liver cancer in patients with alcohol-related liver disease (ARLD).</p><p><strong>Methods: </strong>Patients with ARLD and those with ARLD co-morbid with CHB were included in this study and designated as the ARLD group and the ARLD + HBV group, respectively. Propensity score matching (PSM) was then employed to compare survival rates and liver cancer development between these two groups.</p><p><strong>Results: </strong>Among the 404 patients, 254 were in the ARLD group and 150 in the ARLD + HBV group. After propensity score matching, each group comprised 67 patients. Initially, the ARLD + HBV group exhibited lower 5-year survival rates compared to the ARLD group (51.3% vs. 70.1%, <i>p</i> < 0.001). However, PSM mitigated this difference, with survival rates now comparable (61.2% vs. 60.9%, <i>p</i> = 0.390). Notably, the ARLD + HBV group showed a higher incidence of liver-specific mortality after matching (32.6% vs. 6.2%, <i>p</i> = 0.018). Furthermore, although a higher proportion of patients in the ARLD + HBV group developed liver cancer post-matching, the difference was not statistically significant compared to the ARLD group (15.7% vs. 9.8%, <i>p</i> = 0.170).</p><p><strong>Conclusion: </strong>Co-morbidity with CHB in ARLD patients elevates the risk of liver-related mortality.</p>","PeriodicalId":36518,"journal":{"name":"Health Science Reports","volume":"8 1","pages":"e70257"},"PeriodicalIF":2.1000,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725528/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Science Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/hsr2.70257","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: This study aims to investigate the impact of comorbidity with chronic hepatitis B (CHB) on the survival rates and incidence of liver cancer in patients with alcohol-related liver disease (ARLD).
Methods: Patients with ARLD and those with ARLD co-morbid with CHB were included in this study and designated as the ARLD group and the ARLD + HBV group, respectively. Propensity score matching (PSM) was then employed to compare survival rates and liver cancer development between these two groups.
Results: Among the 404 patients, 254 were in the ARLD group and 150 in the ARLD + HBV group. After propensity score matching, each group comprised 67 patients. Initially, the ARLD + HBV group exhibited lower 5-year survival rates compared to the ARLD group (51.3% vs. 70.1%, p < 0.001). However, PSM mitigated this difference, with survival rates now comparable (61.2% vs. 60.9%, p = 0.390). Notably, the ARLD + HBV group showed a higher incidence of liver-specific mortality after matching (32.6% vs. 6.2%, p = 0.018). Furthermore, although a higher proportion of patients in the ARLD + HBV group developed liver cancer post-matching, the difference was not statistically significant compared to the ARLD group (15.7% vs. 9.8%, p = 0.170).
Conclusion: Co-morbidity with CHB in ARLD patients elevates the risk of liver-related mortality.
目的:本研究旨在探讨慢性乙型肝炎(CHB)合并症对酒精相关性肝病(ARLD)患者生存率和肝癌发病率的影响。方法:将ARLD合并慢性乙型肝炎患者和ARLD合并慢性乙型肝炎患者纳入本研究,分别分为ARLD组和ARLD + HBV组。然后采用倾向评分匹配(PSM)来比较两组之间的生存率和肝癌发展情况。结果:404例患者中,ARLD组254例,ARLD + HBV组150例。倾向评分匹配后,每组67例。最初,与ARLD组相比,ARLD + HBV组的5年生存率较低(51.3%对70.1%,p p = 0.390)。值得注意的是,ARLD + HBV组匹配后肝脏特异性死亡率发生率更高(32.6% vs. 6.2%, p = 0.018)。此外,虽然ARLD + HBV组患者配型后发生肝癌的比例较高,但与ARLD组相比差异无统计学意义(15.7% vs. 9.8%, p = 0.170)。结论:ARLD患者合并CHB可增加肝脏相关死亡风险。